Le Lézard
Classified in: Health
Subjects: PDT, SVY, HSP, ASI, BLK, NTA, DEI

Novel Technology Transforms Baldness Treatment Using Beard and Body Hair


LOS ANGELES, Jan. 8, 2024 /CNW/ -- The ongoing puzzle of having lots of body hair but little on the scalp has confounded many dealing with hair loss. A breakthrough emerges with Dr. U Hair and Skin Clinic reports a pioneering study published in the esteemed Dermatologic Surgery journal titled 'Beard and Body Hair Transplantation by Follicular Unit Excision Using a Skin-Responsive Device.' This publication introduces the revolutionary UGraft Zeus®, a novel skin-responsive device empowering doctors to seamlessly relocate beard and body hair to bald areas on the scalp through a procedure known as body hair transplantation (BHT).

All patients were satisfied with the procedure, with over 79% reporting high satisfaction six months post-procedure.

This comprehensive study, conducted across the US, Colombia, Mexico, and India, delves into the UGraft Zeus's innovative skin-responsive approach, addressing complexities encountered by previous hair restoration techniques. Notably, the UGraft Zeus® distinguishes itself with proprietary design features, including a unique self-navigating capability adept at navigating diverse skin textures, thicknesses, and varying levels of hair curliness during FUE. This capability minimizes graft damage and fosters improved wound healing in all Follicular Unit Extraction (FUE) scenarios, including in BHT.

Across 82 patients with an average age of 48.9 years, the study consistently achieved graft attrition rates below 7% in BHT procedures, marking a significant advancement over prior technologies that reported damage rates as high as 20% (beard) and 30% (body). Impressively, all patients were satisfied with the procedure, with over 79% reporting high satisfaction six months post-procedure. Furthermore, surgeons, previously hesitant to perform BHT using traditional methods, enthusiastically embrace the simplicity and success of the UGraft Zeus®, displaying increased willingness to conduct beard and body FUE procedures.

The importance of BHT emerges as a promising avenue in hair restoration, offering remedies for severe baldness and rectifying issues from unsuccessful previous transplants. Specialized transplants like eyebrows, beards, and eyelashes achieve more natural aesthetic results by utilizing matched body hair characteristics compared to thick but unmatched scalp hair.

Lead author Dr. Sanusi Umar from the Division of Dermatology at Harbor-UCLA, Torrance, and Dr U Hair and Skin Clinic, Manhattan Beach, California, highlights, "The introduction of skin-responsive techniques with the UGraft Zeus® addresses challenges in non-scalp hair transplantation, marking a significant leap in restoring lost hair, irrespective of its severity.

For media inquiries, please contact:
Sara Harutyunyan
Dr. U Hair and Skin Clinic
[email protected] 

SOURCE Dr. U Hair and Skin Clinic


These press releases may also interest you

at 08:30
Toitures Hogue's commitment to providing its employees with a structured, professional working environment that guarantees complete safety in the workplace, both on the job and on the job site, has just been awarded its renewed ISO 45001...

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...



News published on and distributed by: